Clinical Trials

The purpose of this study is to test the hypothesis that subjects with active System Lupus Erythematosus  (SLE) will benefit from correcting their omega-3 deficiency. This will be an add-on to standard of care medication.

This is a multi-center, double-blind, randomized, Phase 2b trial to evaluate the efficacy of atacicept in subjects with systemic lupus erythematosus (SLE).

This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of atacicept in subjects with systemic lupus erythematosus (SLE). The Week 24 visit of ADDRESS II core trial will coincide with the Day 1 visit of this LTE trial.

The purpose of this study to look at certain blood proteins known as complement proteins in the whole blood of patients with systemic lupus erythematosus (SLE or lupus). We propose that the levels of these proteins will A) predict lupus disease activity, B) provide information regarding efficacy of treatment, and c) provide SLE diagnostic information.

The purpose of this study is to assess the safety and tolerability of JNJ-55920839 either as a single ascending intravenous (IV) dose administration in healthy participants or multiple IV dose administrations in patients with mild to moderate Systemic Lupus Erythematosus.

The purpose of this study is to focus on following a prospective cohort of 30 patients with classified SLE for the collection of demographic, clinical (disease activity), and laboratory data that can be used to provide well- characterized biological samples for future assessment of mechanisms of immune dysregulation that lead to clinical disease flare, including a distinct subset of SLE-associated, immune pathway alterations that inform a predictive algorithm. A successful outcome of this proposal will allow for the development of an optimized soluble mediator score, encompassing a distinct subset of informative biomarkers, ready for clinical testing.

The purpose of this study is to understand the characteristics associated with lupus, to assist the early development of new treatments for human lupus and Sjögren's syndrome.

The purpose of this study is to investigate syndecan-1 expression levels on immune cells, especially pDCs, in systemic lupus erythematosus (SLE) patients by flow cytometry, the role of syndecan-1 expressed by SLE patient pDCs in IFN expression, and the role of patient serum in syndecan-1 surface expression on pDCs.

The purpose of this study is to assess the effectiveness and safety of daratumumab in inducing complete or partial remission in patients with active class III or IV (± V) lupus nephritis (LN) as measured by change in proteinuria and serum creatinine.

This observational study is a registry designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).

The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.

The purpose of this study is to evaluate the effectiveness, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment in Participants With Active Lupus Nephritis Class III-IV, +/- V.

The purpose of this trial is to evaluate the effectiveness, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active Lupus Nephritis (LN).

The purpose of this study is to evaluate the effectiveness, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids.

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in adults with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH).

This research trial will study the immune respone to COVID-19 vaccination in patients with rheumatic diseases.

This study is being done to create a "resource" of samples that can be used to improve our ability to diagnose and treat MN, IgAN, MPGN, FSGS/MCD, Lupus Nephritis, AAV, other glomerular tubulo-interstitial disease.

The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B-cell, mantle cell and follicular lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including  systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models.